Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Moderator: John Shah 17:00 Close
Investigator, Molecular Discovery Research Conference Producer
GlaxoSmithKline
This interactive workshop will provide a comprehensive overview of label-free cell-based
This document provides information about the "Cell Based Assays Americas" conference to be held on July 19-20, 2012 in Boston, USA. The conference will focus on advances in cell-based assays for drug discovery, development and toxicity testing. It will explore new techniques and applications of cell-based assays, including their use in reducing costs and risks in the drug development process. Speakers will discuss topics like high content screening strategies, 3D tissue models, stem cell technologies and interpreting results from cell-based assays. The agenda provides details of presentations on developing cell-based assay platforms and applications in areas like neurodegeneration, cardiotoxicity screening and kinase inhibitor mechanisms of action. The conference aims to highlight future growth opportunities in
Jacqueline Vet runs a company called NYtor that develops molecular diagnostic assays using quantitative PCR (qPCR) and molecular beacon technology. NYtor works on contract research projects and aims to license developed assays to suitable partners. Current projects include developing a rapid qPCR assay to detect antibiotic-resistant bacteria for use in hospitals. NYtor is also working with another company to develop personalized medicine assays. Future goals include expanding multiplex capabilities and moving to microarray-based formats. Key challenges will be expanding facilities, hiring the right staff, obtaining financing, and refining the business strategy.
2nd Annual Cell Based Assays (2011) PpPiyush Patel
This document announces the 2nd Annual Cell-Based Assays conference taking place from October 11-13, 2011 in London. The conference will focus on optimizing methods and integrating new platforms for drug discovery, development, and toxicity testing using cell-based assays. Key speakers from various pharmaceutical companies will discuss topics like high-content screening, G protein-coupled receptors, kinases, primary cells, computational models, 3D cell assays, and stem cells. The conference aims to help attendees utilize new techniques in high-throughput screening and accelerate drug development using more advanced cell-based models and assays.
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Dr. Nick Thomas 17:00 - 17:30 Closing Remarks & Networking Drinks
Investigator, Molecular Discovery Research Principal Scientist
Glax
PepTalk: The Protein Science Week is an annual gathering where industry experts from around the world convene to share case studies, unpublished data, breakthroughs and solutions that support and enhance research, and to gain new perspectives on the evolution of biologics.
Cell based assays presentation v3_03_2012Pete Shuster
Update presentation on "increasing returns in drug discovery by harnessing the power of cells". Includes images/data/pubs of differentiating human sensory and dopaminergic neurons from hNP1 neural progenitors + osteoblasts and chondrocytes from human mesenchymal stem cells. Our platforms are ideal for high throughput screening and other drug discovery processes.
The Life Science Product Manager's Toolkitprothenberg
A discussion about market research tools that can optimize each stage of the new product development process. Prepared by BioInformatics LLC exclusively for life science product and marketing managers.
This document provides an overview of local biotech companies in Hong Kong Science and Technology Parks (HKSTP). It summarizes 15 diagnostic companies from local universities in HKSTP, including those from Chinese University (CUHK), University of Hong Kong (HKU), University of Science and Technology (UST), and Hong Kong Baptist University (HKBU). It highlights several local high-fliers, including Prof. Dennis Lo from CUHK who founded Arbele and Xcelom, and Prof. Michael Yang from CityU who founded Multigene Diagnostics and Genetel Pharmaceuticals. It also discusses trends in personalized medicine, obstacles, and examples of novel designs and a start-up biotech company to illustrate
This document provides information about the "Cell Based Assays Americas" conference to be held on July 19-20, 2012 in Boston, USA. The conference will focus on advances in cell-based assays for drug discovery, development and toxicity testing. It will explore new techniques and applications of cell-based assays, including their use in reducing costs and risks in the drug development process. Speakers will discuss topics like high content screening strategies, 3D tissue models, stem cell technologies and interpreting results from cell-based assays. The agenda provides details of presentations on developing cell-based assay platforms and applications in areas like neurodegeneration, cardiotoxicity screening and kinase inhibitor mechanisms of action. The conference aims to highlight future growth opportunities in
Jacqueline Vet runs a company called NYtor that develops molecular diagnostic assays using quantitative PCR (qPCR) and molecular beacon technology. NYtor works on contract research projects and aims to license developed assays to suitable partners. Current projects include developing a rapid qPCR assay to detect antibiotic-resistant bacteria for use in hospitals. NYtor is also working with another company to develop personalized medicine assays. Future goals include expanding multiplex capabilities and moving to microarray-based formats. Key challenges will be expanding facilities, hiring the right staff, obtaining financing, and refining the business strategy.
2nd Annual Cell Based Assays (2011) PpPiyush Patel
This document announces the 2nd Annual Cell-Based Assays conference taking place from October 11-13, 2011 in London. The conference will focus on optimizing methods and integrating new platforms for drug discovery, development, and toxicity testing using cell-based assays. Key speakers from various pharmaceutical companies will discuss topics like high-content screening, G protein-coupled receptors, kinases, primary cells, computational models, 3D cell assays, and stem cells. The conference aims to help attendees utilize new techniques in high-throughput screening and accelerate drug development using more advanced cell-based models and assays.
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Dr. Nick Thomas 17:00 - 17:30 Closing Remarks & Networking Drinks
Investigator, Molecular Discovery Research Principal Scientist
Glax
PepTalk: The Protein Science Week is an annual gathering where industry experts from around the world convene to share case studies, unpublished data, breakthroughs and solutions that support and enhance research, and to gain new perspectives on the evolution of biologics.
Cell based assays presentation v3_03_2012Pete Shuster
Update presentation on "increasing returns in drug discovery by harnessing the power of cells". Includes images/data/pubs of differentiating human sensory and dopaminergic neurons from hNP1 neural progenitors + osteoblasts and chondrocytes from human mesenchymal stem cells. Our platforms are ideal for high throughput screening and other drug discovery processes.
The Life Science Product Manager's Toolkitprothenberg
A discussion about market research tools that can optimize each stage of the new product development process. Prepared by BioInformatics LLC exclusively for life science product and marketing managers.
This document provides an overview of local biotech companies in Hong Kong Science and Technology Parks (HKSTP). It summarizes 15 diagnostic companies from local universities in HKSTP, including those from Chinese University (CUHK), University of Hong Kong (HKU), University of Science and Technology (UST), and Hong Kong Baptist University (HKBU). It highlights several local high-fliers, including Prof. Dennis Lo from CUHK who founded Arbele and Xcelom, and Prof. Michael Yang from CityU who founded Multigene Diagnostics and Genetel Pharmaceuticals. It also discusses trends in personalized medicine, obstacles, and examples of novel designs and a start-up biotech company to illustrate
The document announces the Cell Based Assays Conference to be held on June 26-27, 2012 in London. The conference will feature keynote speakers who will provide updates on cell based assays and their importance in pharmaceutical research. Sessions over the two days will cover topics like high-content screening, 3D cell models, GPCR signaling pathways, and applications of cell based assays in drug discovery. The conference is aimed at researchers in fields related to screening, pharmacology, and assay development.
Cell based assays presentation V2_03_2012Pete Shuster
This document provides an executive overview of a company called Neuromics/Vitro Biopharma that develops pre-clinical tools for drug discovery using human stem cell-derived cell systems. The company offers physiologically relevant human cells and cellular systems to enable better in vitro screening and target identification, reducing animal models and shortening development timelines. Key offerings include human stem cell-derived neuronal cells, glial cells, immune cells and other cell types, specialized media, transfection reagents, markers and labeling technologies. The company aims to improve early drug discovery through more predictive human cell-based assays.
The document discusses the high failure rate and costs of drug development, and the need for new solutions to address safety and efficacy challenges. It introduces biomarkers as a key solution, noting they can help improve discovery, clinical development, and portfolio management by identifying drugs more likely to succeed in early trials. Biomarker services aim to determine proof-of-concept earlier at lower cost by providing predictive indicators of drug function, response, efficacy, and safety through tissue analysis and protein detection.
Biovays is a biomarker solutions provider that offers specialized services to support drug development from target discovery through FDA approval. Their services include biomarker selection and assay development, pharmacodynamics testing, toxicity analysis, and various in vitro and ex vivo assays. By providing biomarker analysis and expertise, Biovays aims to streamline drug development, reduce costs, and improve success rates.
This document provides information about the 6th Drug Discovery for Neurodegeneration Conference held on February 12-14, 2012 in New York City. The conference aimed to provide an intensive course on translating research into drugs for neurodegenerative diseases. It was funded in part by the National Institute on Aging and had over 190 attendees from 20 countries. The scientific advisory committee included experts from various academic and research institutions. The goals of the meeting were to share knowledge on drug discovery principles and practices for neurodegenerative diseases and foster networking and collaboration. Neurodegenerative diseases pose major challenges for drug development but also opportunities to develop novel treatments.
Holistic Approaches to Virus Risk MitigationMilliporeSigma
Presented at INTERPHEX on March 21-23, 2017.
Regulatory guidelines have shaped industry best practices around adventitious virus contamination risk mitigation in terms of patient safety. A recent survey indicated that the cost to remediate a virus contamination can run into millions of dollars, not including commercial impact. Today, the industry is taking a closer look at minimizing the business risk associated with viral contaminations and is taking a more holistic view of risk mitigation. This approach includes virus prevention and detection in addition to removal. From cell culture seed train to final fill vial, the discussion will describe the potential risks associated with different areas of biotech processes and what can be done to minimize adventitious virus risk in those areas. The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, testing and regulatory considerations.
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
WuXi AppTec Medical Device Preclincal Testing ServicesMichaelMoulsoff
WuXi AppTec is a leading pharmaceutical, biotech, and medical device R&D outsourcing company with over 4,000 employees across facilities in China and the United States. It offers a range of laboratory, manufacturing, and testing services to over 800 clients worldwide, focusing on pharmaceuticals, biologics, combination products, and medical devices. WuXi AppTec has over 2 million square feet of laboratory, animal, and manufacturing facilities across China and the US that allow it to provide full development and regulatory support to clients.
Keeping the (Adventitious) Virus Out of the (Adeno-Associated) VirusMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/2VRylbi
How can you keep an adventitious virus from contaminating your gene therapy that is delivered by an adeno virus vector? As viral vector bioprocessing advances, regulatory requirements for viral safety will as well. Learn how to define your viral clearance strategy for AAV delivered gene therapies.
How do you define a strategy for viral clearance for a process that inherently aims at purifying a virus?
Gene delivery using AAV has received a boost from two major approvals and the nearly 300 programs in the clinic. Novel gene therapies using viral vectors enable companies to transform the lives of people living with certain rare and ultra-rare diseases where treatments are often not available currently. Amongst a multitude of challenges in viral vector bioprocessing, uncertainty in regulatory expectations is a major challenge to gene therapy developers. Regulatory requirements are evolving as the science and manufacturing matures with more stringent measures for viral safety assurance expected for future approvals.
Learn how to implement techniques for adventitious virus removal in your viral vector process; we will focus on strategies for viral clearance along your journey towards commercial readiness of AAV-based processes.
In this webinar, you will learn:
• AAV process flows and focus areas for viral safety
• Strategies for implementing viral clearance measures in bioprocessing
• Case studies and data driven approaches on log reduction values (LRV) in a viral vector process
• Best practices and evaluation roadmaps on conducting viral clearance studies
Presented by: Ratish Krishnan, Senior Strategy Consultant, Novel Modalities Bioprocessing
company presentation. Development of the prostate cancer diagnostic test and in-vitro diagnostic device for the point-of-care diagnosis of prostate cancer
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsMerck Life Sciences
Learn about existing and emerging methods to accelerate biosafety testing of biologic therapies.
Speed to market for biologic therapeutics is ever more critical. However, the critical safety tests for these molecules, for example screening for adventitious agents such as viral contaminants, can be time consuming as well as challenging and laborious. Join us for this webinar as we explore how rapid methodologies are being used to not only accelerate this process, but also enhance quality by reducing testing complexity. Existing technologies as well as emerging trends will be discussed, along with the implications these may have on the regulatory landscape.
In this webinar you will learn:
● Which existing and emerging technologies are having now, and will have in the future, an impact on biosaftey testing.
● The benefits as well as risks of employing rapid methods for biosafety screening.
● How the regulatory agencies are reacting to rapid testing methods as alternatives to existing methods.
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
Latest Updates in Biosafety Testing for Gene TherapyMilliporeSigma
The document discusses the latest regulatory expectations and challenges for biosafety testing of gene therapies, including how to design a robust safety testing strategy to test for bacteria, fungi, mycoplasma, endotoxins, and adventitious viruses using methods such as sterility testing, PCR assays, and in vivo and in vitro testing. It also covers emerging areas like next generation sequencing, replication competent AAV detection, and characterization of residual DNA levels.
PPT Cirillo "I Stage: from Koch to Xpert"StopTb Italia
This document discusses advances and limitations in the diagnosis of tuberculosis. It outlines how microscopy has been the standard diagnostic method for over a century but has limitations in sensitivity. Molecular diagnostics like the Xpert MTB/RIF test have improved sensitivity over microscopy but still have limitations for diagnosing TB in children and extrapulmonary cases. Current molecular tests and culture-based drug susceptibility testing can be challenging to implement widely due to infrastructure and technical limitations. Overall, diagnosis of TB, particularly for difficult cases, remains imperfect even with new technologies.
The document discusses next generation molecular profiling and personalized medicine. It begins by describing the lab, which has 10 genome hackers and 42 scientists working on projects involving hardware engineering, mathematics, and molecular biology. It then discusses the benefits of personalized medicine using biomarkers to identify which patients will respond best to certain therapies. The document outlines first generation molecular profiling techniques like microarrays and sequencing and compares them to next generation techniques like Roche's 454 sequencing which can generate more data at a lower cost and higher throughput. It notes the shift to more targeted, personalized treatment approaches using molecular information.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
Vitreous biopsy can aid in diagnosing uveitis when clinical presentation is non-specific or atypical. A vitreous specimen can be obtained via vitreous aspiration or pars plana vitrectomy, with the latter preferred as it removes more vitreous and reduces risks. The vitreous can be analyzed through microbiological and PCR analysis, cytopathological analysis, flow cytometry, immunohistochemistry, and determining antibody and cytokine levels to diagnose infectious agents, malignancies, or inflammatory conditions causing uveitis.
Wu xi apptec lab testing division overview 2016Linda Zhao
WuXi AppTec's Laboratory Testing Division is a large growth engine that provides integrated testing solutions to support drug development, clinical diagnostics, and medical device testing. It has over 1,600 employees across sites in China and the US. The division offers a full range of preclinical and clinical services, including CMC development, safety and efficacy testing, bioanalysis, and biomarker analysis. It also has platforms for in vitro diagnostics and medical device testing. The division aims to transform scientific ideas into healthcare products to better serve patients.
How to make create genomic research target molecules drug discovery strategy ...SlideTeam.net
The drug discovery process involves several steps:
1) Identification of a biological target like receptors or enzymes.
2) Discovery of seed compounds that can bind to the target through high-throughput screening.
3) Scrutiny of potential drug candidates where their efficacy and safety are estimated.
How to make create genomic research target molecules drug discovery strategy ...SlideTeam.net
The document outlines the key steps in the drug discovery process:
1. Identification of target molecules through genomic research and functional analysis of genes and enzymes.
2. Discovery of seed lead compounds through high-throughput screening and combinatorial chemistry.
3. Scrutiny of drug candidates including estimation of drug efficacy and safety evaluation.
4. Manufacturing development and clinical studies prior to new drug application and launch.
The document is an invitation to the "Anti-Counterfeiting Americas" conference on November 8-9, 2010 in Boston. The conference will provide insights into issues related to securing the pharmaceutical supply chain and tracking technologies. Key topics will include tackling counterfeit drugs, improving distribution integrity, and collaboration against counterfeiting. Attendees will gain an understanding of supply chain challenges and investment potential in pharmaceutical logistics. The conference will feature speakers from organizations focused on supply chain security and counterfeit drug prevention.
A syringe is essentially a device used in medicine to inject fluid into or withdraw fluid from the body. Medical syringes consist of a needle attached to a hollow cylinder that is fitted with a sliding plunger. The downward movement of the plunger injects fluid; upward movement withdraws fluid. A prefilled syringe is a single-dose packet of vaccine to which a needle has been fixed by the manufacturer. A prefilled syringe is not positioned as a high technology product such as needle free injectors which involves pioneering drug delivery technologies. Neither is it a simple technology (for example tabulating). Instead it is positioned in the middle, being on the border line of simple to advance.
The growth rate is to be expected to remain at a high level of more than 10% annually. This is due to a number of factors such as greater medication safety and increased convenience from using a prefillable device.
Prefilled syringes accommodate volumes that typically range from 0.25 to 5.0 ml. They are therefore best suited to products administered by subcutaneous or intramuscular injection. The categories account for the bulk of prefilled syringes: vaccines, blood stimulants, therapeutic proteins, erythroproteins, interferons and rheumatoid arthritis
The document announces the Cell Based Assays Conference to be held on June 26-27, 2012 in London. The conference will feature keynote speakers who will provide updates on cell based assays and their importance in pharmaceutical research. Sessions over the two days will cover topics like high-content screening, 3D cell models, GPCR signaling pathways, and applications of cell based assays in drug discovery. The conference is aimed at researchers in fields related to screening, pharmacology, and assay development.
Cell based assays presentation V2_03_2012Pete Shuster
This document provides an executive overview of a company called Neuromics/Vitro Biopharma that develops pre-clinical tools for drug discovery using human stem cell-derived cell systems. The company offers physiologically relevant human cells and cellular systems to enable better in vitro screening and target identification, reducing animal models and shortening development timelines. Key offerings include human stem cell-derived neuronal cells, glial cells, immune cells and other cell types, specialized media, transfection reagents, markers and labeling technologies. The company aims to improve early drug discovery through more predictive human cell-based assays.
The document discusses the high failure rate and costs of drug development, and the need for new solutions to address safety and efficacy challenges. It introduces biomarkers as a key solution, noting they can help improve discovery, clinical development, and portfolio management by identifying drugs more likely to succeed in early trials. Biomarker services aim to determine proof-of-concept earlier at lower cost by providing predictive indicators of drug function, response, efficacy, and safety through tissue analysis and protein detection.
Biovays is a biomarker solutions provider that offers specialized services to support drug development from target discovery through FDA approval. Their services include biomarker selection and assay development, pharmacodynamics testing, toxicity analysis, and various in vitro and ex vivo assays. By providing biomarker analysis and expertise, Biovays aims to streamline drug development, reduce costs, and improve success rates.
This document provides information about the 6th Drug Discovery for Neurodegeneration Conference held on February 12-14, 2012 in New York City. The conference aimed to provide an intensive course on translating research into drugs for neurodegenerative diseases. It was funded in part by the National Institute on Aging and had over 190 attendees from 20 countries. The scientific advisory committee included experts from various academic and research institutions. The goals of the meeting were to share knowledge on drug discovery principles and practices for neurodegenerative diseases and foster networking and collaboration. Neurodegenerative diseases pose major challenges for drug development but also opportunities to develop novel treatments.
Holistic Approaches to Virus Risk MitigationMilliporeSigma
Presented at INTERPHEX on March 21-23, 2017.
Regulatory guidelines have shaped industry best practices around adventitious virus contamination risk mitigation in terms of patient safety. A recent survey indicated that the cost to remediate a virus contamination can run into millions of dollars, not including commercial impact. Today, the industry is taking a closer look at minimizing the business risk associated with viral contaminations and is taking a more holistic view of risk mitigation. This approach includes virus prevention and detection in addition to removal. From cell culture seed train to final fill vial, the discussion will describe the potential risks associated with different areas of biotech processes and what can be done to minimize adventitious virus risk in those areas. The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, testing and regulatory considerations.
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
WuXi AppTec Medical Device Preclincal Testing ServicesMichaelMoulsoff
WuXi AppTec is a leading pharmaceutical, biotech, and medical device R&D outsourcing company with over 4,000 employees across facilities in China and the United States. It offers a range of laboratory, manufacturing, and testing services to over 800 clients worldwide, focusing on pharmaceuticals, biologics, combination products, and medical devices. WuXi AppTec has over 2 million square feet of laboratory, animal, and manufacturing facilities across China and the US that allow it to provide full development and regulatory support to clients.
Keeping the (Adventitious) Virus Out of the (Adeno-Associated) VirusMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/2VRylbi
How can you keep an adventitious virus from contaminating your gene therapy that is delivered by an adeno virus vector? As viral vector bioprocessing advances, regulatory requirements for viral safety will as well. Learn how to define your viral clearance strategy for AAV delivered gene therapies.
How do you define a strategy for viral clearance for a process that inherently aims at purifying a virus?
Gene delivery using AAV has received a boost from two major approvals and the nearly 300 programs in the clinic. Novel gene therapies using viral vectors enable companies to transform the lives of people living with certain rare and ultra-rare diseases where treatments are often not available currently. Amongst a multitude of challenges in viral vector bioprocessing, uncertainty in regulatory expectations is a major challenge to gene therapy developers. Regulatory requirements are evolving as the science and manufacturing matures with more stringent measures for viral safety assurance expected for future approvals.
Learn how to implement techniques for adventitious virus removal in your viral vector process; we will focus on strategies for viral clearance along your journey towards commercial readiness of AAV-based processes.
In this webinar, you will learn:
• AAV process flows and focus areas for viral safety
• Strategies for implementing viral clearance measures in bioprocessing
• Case studies and data driven approaches on log reduction values (LRV) in a viral vector process
• Best practices and evaluation roadmaps on conducting viral clearance studies
Presented by: Ratish Krishnan, Senior Strategy Consultant, Novel Modalities Bioprocessing
company presentation. Development of the prostate cancer diagnostic test and in-vitro diagnostic device for the point-of-care diagnosis of prostate cancer
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsMerck Life Sciences
Learn about existing and emerging methods to accelerate biosafety testing of biologic therapies.
Speed to market for biologic therapeutics is ever more critical. However, the critical safety tests for these molecules, for example screening for adventitious agents such as viral contaminants, can be time consuming as well as challenging and laborious. Join us for this webinar as we explore how rapid methodologies are being used to not only accelerate this process, but also enhance quality by reducing testing complexity. Existing technologies as well as emerging trends will be discussed, along with the implications these may have on the regulatory landscape.
In this webinar you will learn:
● Which existing and emerging technologies are having now, and will have in the future, an impact on biosaftey testing.
● The benefits as well as risks of employing rapid methods for biosafety screening.
● How the regulatory agencies are reacting to rapid testing methods as alternatives to existing methods.
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
Latest Updates in Biosafety Testing for Gene TherapyMilliporeSigma
The document discusses the latest regulatory expectations and challenges for biosafety testing of gene therapies, including how to design a robust safety testing strategy to test for bacteria, fungi, mycoplasma, endotoxins, and adventitious viruses using methods such as sterility testing, PCR assays, and in vivo and in vitro testing. It also covers emerging areas like next generation sequencing, replication competent AAV detection, and characterization of residual DNA levels.
PPT Cirillo "I Stage: from Koch to Xpert"StopTb Italia
This document discusses advances and limitations in the diagnosis of tuberculosis. It outlines how microscopy has been the standard diagnostic method for over a century but has limitations in sensitivity. Molecular diagnostics like the Xpert MTB/RIF test have improved sensitivity over microscopy but still have limitations for diagnosing TB in children and extrapulmonary cases. Current molecular tests and culture-based drug susceptibility testing can be challenging to implement widely due to infrastructure and technical limitations. Overall, diagnosis of TB, particularly for difficult cases, remains imperfect even with new technologies.
The document discusses next generation molecular profiling and personalized medicine. It begins by describing the lab, which has 10 genome hackers and 42 scientists working on projects involving hardware engineering, mathematics, and molecular biology. It then discusses the benefits of personalized medicine using biomarkers to identify which patients will respond best to certain therapies. The document outlines first generation molecular profiling techniques like microarrays and sequencing and compares them to next generation techniques like Roche's 454 sequencing which can generate more data at a lower cost and higher throughput. It notes the shift to more targeted, personalized treatment approaches using molecular information.
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
Vitreous biopsy can aid in diagnosing uveitis when clinical presentation is non-specific or atypical. A vitreous specimen can be obtained via vitreous aspiration or pars plana vitrectomy, with the latter preferred as it removes more vitreous and reduces risks. The vitreous can be analyzed through microbiological and PCR analysis, cytopathological analysis, flow cytometry, immunohistochemistry, and determining antibody and cytokine levels to diagnose infectious agents, malignancies, or inflammatory conditions causing uveitis.
Wu xi apptec lab testing division overview 2016Linda Zhao
WuXi AppTec's Laboratory Testing Division is a large growth engine that provides integrated testing solutions to support drug development, clinical diagnostics, and medical device testing. It has over 1,600 employees across sites in China and the US. The division offers a full range of preclinical and clinical services, including CMC development, safety and efficacy testing, bioanalysis, and biomarker analysis. It also has platforms for in vitro diagnostics and medical device testing. The division aims to transform scientific ideas into healthcare products to better serve patients.
How to make create genomic research target molecules drug discovery strategy ...SlideTeam.net
The drug discovery process involves several steps:
1) Identification of a biological target like receptors or enzymes.
2) Discovery of seed compounds that can bind to the target through high-throughput screening.
3) Scrutiny of potential drug candidates where their efficacy and safety are estimated.
How to make create genomic research target molecules drug discovery strategy ...SlideTeam.net
The document outlines the key steps in the drug discovery process:
1. Identification of target molecules through genomic research and functional analysis of genes and enzymes.
2. Discovery of seed lead compounds through high-throughput screening and combinatorial chemistry.
3. Scrutiny of drug candidates including estimation of drug efficacy and safety evaluation.
4. Manufacturing development and clinical studies prior to new drug application and launch.
The document is an invitation to the "Anti-Counterfeiting Americas" conference on November 8-9, 2010 in Boston. The conference will provide insights into issues related to securing the pharmaceutical supply chain and tracking technologies. Key topics will include tackling counterfeit drugs, improving distribution integrity, and collaboration against counterfeiting. Attendees will gain an understanding of supply chain challenges and investment potential in pharmaceutical logistics. The conference will feature speakers from organizations focused on supply chain security and counterfeit drug prevention.
A syringe is essentially a device used in medicine to inject fluid into or withdraw fluid from the body. Medical syringes consist of a needle attached to a hollow cylinder that is fitted with a sliding plunger. The downward movement of the plunger injects fluid; upward movement withdraws fluid. A prefilled syringe is a single-dose packet of vaccine to which a needle has been fixed by the manufacturer. A prefilled syringe is not positioned as a high technology product such as needle free injectors which involves pioneering drug delivery technologies. Neither is it a simple technology (for example tabulating). Instead it is positioned in the middle, being on the border line of simple to advance.
The growth rate is to be expected to remain at a high level of more than 10% annually. This is due to a number of factors such as greater medication safety and increased convenience from using a prefillable device.
Prefilled syringes accommodate volumes that typically range from 0.25 to 5.0 ml. They are therefore best suited to products administered by subcutaneous or intramuscular injection. The categories account for the bulk of prefilled syringes: vaccines, blood stimulants, therapeutic proteins, erythroproteins, interferons and rheumatoid arthritis
The 4th Annual Contract Manufacturing conference will be held on December 13-14, 2010 in London. The conference will provide strategies and case studies on implementing Quality by Design (QbD) and Process Analytical Technology (PAT) to improve contract manufacturing relationships. Speakers from pharmaceutical companies like AstraZeneca, Novartis, and Amylin will discuss best practices for technology transfer, analytical methods validation, and managing contract manufacturing organizations throughout a product's lifecycle. The conference aims to help attendees maximize outsourcing opportunities and choose the right CMO partners.
This document provides information about the "CNS Clinical Trials" conference taking place on September 16-17, 2010 in London. The conference will examine strategies for successful CNS drug development and overcoming challenges in clinical trial design, management, and recruitment. Key topics will include novel cognitive assessment methods, advances in neuroimaging, adaptive trial design, and the use of biomarkers to demonstrate early drug effects in CNS trials. Speakers will include representatives from pharmaceutical and biotechnology companies as well as academic institutions. Attendees will gain insights on improving various aspects of CNS clinical trials from development through regulatory approval. The conference also provides sponsorship and exhibition opportunities for companies to promote their products and services.
This document provides information about the "Vaccine Research & Innovation 2010" conference taking place on September 2-3, 2010 in London. The conference will explore opportunities in vaccine research and development and feature key speakers from companies such as Novartis Vaccines, Merck, and Intercell. Attendees will gain insights into topics like overcoming challenges in cancer vaccine development, evaluating immune responses to combination vaccines, and implementing strategies for manufacturing conjugate vaccines. The conference is designed to share successful strategies and innovative technologies for developing more effective vaccines.
This document provides information about an upcoming conference on pre-filled syringes. It outlines the conference details including dates, location, key speakers from companies like Merck Serono and AstraZeneca. It also lists media partners, sponsors, and exhibitors. The document discusses the growing market for pre-filled syringes and challenges in the industry. It promotes the conference as a chance to learn about new developments, network, and address issues like drug compatibility and manufacturing processes. A pre-conference workshop on legal issues is also advertised.
This is a conference about drug discovery and drug development. G protein-coupled receptor (GPCR) and protein kinases are the biggest drug targets in medicine. Around half of all drugs, for whatever disease, work by interacting with different GPCRs and kinases.
This document discusses the mechanisms of hormone and neurotransmitter action in the body. It describes the different types of receptors, including membrane receptors and intracellular receptors. It also explains the various signal transduction pathways triggered by receptors, such as G protein-coupled receptors that activate adenylate cyclase or phospholipase C, receptors with intrinsic enzymatic activity like guanylate cyclase, and receptors with tyrosine kinase activity like the insulin receptor. The key second messengers produced by these pathways, like cAMP, Ca2+, cGMP, and phosphorylated proteins, are also outlined.
This document provides information about an upcoming conference on 4th Pre-Filled Syringes that will address challenges in developing efficacious pre-filled syringe products. The conference will take place from October 17-19, 2011 in London and will feature key speakers from companies such as AstraZeneca, Novartis, Bayer, and the UK Medicines and Healthcare products Regulatory Agency (MHRA). It will include topics such as manufacturing, formulation, quality, safety, and novel pre-filled syringe technologies. Attendees can gain insights on issues like ensuring drug identity, potency and sterility in pre-filled syringes.
SMi Group's 7th annual Advances in Cell Based Assays conferenceDale Butler
This document summarizes a two-day conference on advances in cell-based assays being held on November 11-12, 2014 in London. The conference will explore the latest developments in cell-based assays and their application in drug discovery and development. Speakers will include representatives from pharmaceutical companies such as GSK, AstraZeneca, Novartis, UCB, and Merck Serono, as well as academics. Topics will include the use of cell-based assays in biologics drug discovery, challenges in validation and regulation, phenotypic screening, stem cell technologies, and 3D cell cultures. Workshops on leveraging cell-based assays for open innovation and evaluating cell-based assays in drug discovery will also be offered
The Clinical Trial in Oncology event on 1-2 December 2009 in Munich will show you how to utilise target approaches to optimize your clinical research and enhance your patient enrolment, data quality and much more.
P 058 Advances And Progress In Drug Designkprior88
SMi\'s 12th Annual Drug Design Conference will present attendees with an in-depth view into the developments and challenges within the Drug Design field
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Scientia Advisors Impact Of Microarray In M Dx Oct 2008glorikian
The document summarizes a report by Scientia Advisors on the impact of DNA microarrays on molecular diagnostics. It provides an overview of the microarray market for molecular diagnostics, which is currently small but growing rapidly. Key drivers of growth include the ability of microarrays to profile multiple genes and pathways involved in complex diseases like cancer. The document also discusses regulatory requirements, reimbursement challenges, examples of microarray-based diagnostic tests, and emerging array technologies that could increase clinical adoption if assay time, ease of use, and reproducibility are improved.
The document discusses challenges and opportunities in the development of biosimilars. It provides perspectives from several industry experts on the top hurdle being a lack of clarity around intellectual property and marketing strategies as well as high development costs. The experts note that developing the necessary skill sets around quality by design, analytics, and clinical trial design is key to overcoming hurdles in developing biosimilars safely and effectively.
This document provides information about the 12th Annual Conference and Exhibition on ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) taking place from June 12-14, 2017 in London. The conference will address early ADME application strategies and discuss the latest screening and testing models. It will feature talks from industry leaders on topics including predictive toxicity, PK optimization, preclinical testing, drug screening technologies, and physiologically-based PK modeling. A workshop on drug transporters will also be held on the third day.
An overview of the oncology clinical trials network (CTNeT) which is being implemented throughout Texas.
The non-profit network is a first of its kind and combines the innovative science of Texas cancer centers with the expertise and resources of both academic and community oncologists throughout the state.
To learn more, visit www.ctnet.org
A biomarker strategy aims to answer key clinical questions to support drug development through identifying and testing biomarkers. Developing a robust biomarker strategy can mitigate risks and inform clinical study design by generating testable hypotheses to bridge pre-clinical and clinical research. Effective biomarker strategies consider assay suitability, study design, and sample availability to reliably detect biomarkers and provide statistically meaningful results. Emerging technologies allow deeper interrogation of drugs and disease through multiplexed readouts to enhance biomarker discovery and clinical development.
This document summarizes the work of a team developing a company called CanScan to advance personalized cancer treatment. The team cultured circulating tumor cells (CTCs) from blood samples to characterize cancer cell aggressiveness and test drug responses. Key findings included that culturing CTCs could provide valuable data to guide treatment decisions. The team refined their business model to partner with diagnostic companies and provide CTC testing services to oncologists and pharmaceutical companies. Next steps involved further validating the technology and business through clinical trials and partnerships.
Innovation in Phase 1 Clinical DevelopmentElisa_Ramella
Practical app roaches to
phase I trial develop ment
to enable faster go / no -go
decision s, reduce co st and
speed time to market
www.phase1clinicaldevelopment.com
The Pistoia Alliance is examining the challenges of the Faster Safe Companion Diagnostics (CDx) by Aligning Discovery & Clinical Data in the Regulatory Domain.
The slides discuss whether the data standards used in the research environment be aligned better with the data standards used in the regulated environment? If so, the time and cost of the development of NGS-based CDx could be reduced.
The conference will provide an interactive networking forum to both further develop and answer your queries through a vibrant exhibition room full of technology providers showcasing their technologies and other solutions, poster presentation sessions, expert led case study presentations, a high-level panel discussion, a round table discussion session, and interactive Q&A sessions from a 40-strong speaker faculty examining topics on 4 separate tracks outlined below.
Blueprints to blue sky – analyzing the challenges and solutions for IHC compa...Candy Smellie
Manual assessment of biomarker expression is associated with significant inter- and intra reader variability. In some cases there are also limitations when it comes to sensitivity and specificity of manual biomarker assessment.
In one example to the left, the “pure” contribution of inter-reader variability associated with Ki67 assessment was quantified across 20 tumors and 126 participating labs. In that study, it was demonstrated how image analysis can be used to significantly reduce inter-reader variability.
In a another study, the National Danish Validation study of Her2, it was demonstrated how improved sensitivity/specificity of quantitative HER2 protein expression wrt gene amplification lead to significant cost savings in reflex testing.
By automating aspects of stain quality control, it will become scalable to he point where EQA organizations may be able and willing to offer more frequent – perhaps even on-demand – proficiency testing and calibration services.
It is possible that objective and quantitative standards will contribute to improve compliance with protocol recommendations.
In clinical multi-center trials it will be easier to standardize and monitor data from each center.
And it is our hope tha larger diagnostic pathology labs will be able to benefit from such a method by closely monitoring drift in staining quality for biomarkers.
This document announces a conference on monoclonal antibodies to be held on March 19-20, 2013 in London. The conference will explore innovation in therapeutic antibody development and production. Over the two days, speakers from companies like Pfizer, GlaxoSmithKline, Novartis, Roche, and Lonza will give presentations on topics such as monoclonal antibody characterization, immunogenicity assessment, bispecific antibodies, and antibody engineering. There will also be a panel discussion on the future of monoclonal antibody development over the next decade.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes an upcoming conference on biobanking in the Americas from June 7-9, 2011 in Boston. It will bring together experts from biobanks, pharmaceutical companies, biotech firms, and regulatory agencies to discuss strategic approaches to biosample management and using biobanks to enable next-generation drug discovery and personalized medicine. Speakers will provide practical knowledge on new biobanking models, address ethical and legal challenges, and explore how to leverage biospecimen resources to support biomarker research. Attendees will learn best practices for biorepository management and implementation, applications of genome sequencing, and strategies for building biomarker discovery pipelines. The conference aims to facilitate networking and enable confident decision making through benchmarking against
Pharmaceutical Product & Process Design & QualityAjaz Hussain
A reflection on progress made, and challenges to be addressed, in realizing the desired state articulated by the the FDA Initiative on Pharmaceutical Quality for the 21st Century.
BioOutsource is a company that provides testing services for biologics and vaccines to ensure quality and safety. They offer a unique combination of scientific expertise and innovative IT solutions embedded in a GMP-compliant environment. Services include cell-based assays for safety and potency testing of vaccines and biologics, molecular biology techniques like PCR for virus detection and residual DNA testing, and analytical protein tests. All services are performed according to GMP standards using validated methods. Client documentation and test results are securely stored and accessible through their web-based system.
1. Cell-Based Assays
Optimising methods and integrating new platforms for drug discovery, development and toxicity testing
20th - 22nd September 2010, BSG Conference Centre, London, UK BOOK NOW!
Key Speakers
Dr. Maria Flocco, Senior Director, Lead Discovery and Structural Biology & Biophysics, Pfizer
Dr. Magalie Rocheville, Investigator, Molecular Discovery Research, GlaxoSmithKline
Dr. Priya Kunapuli, Director, In Vitro Sciences, External Discovery and Pre-Clinical Sciences, Merck Research Laboratories
Dr. Stefan O. Mueller, Global Head, Early, Genetic and Molecular Toxicology, Merck Serono
Dr. Alastair Brown, Associate Principal Scientist, AstraZeneca
Dr. Rochdi Bouhelal, Senior Investigator, Novartis
Dr. Nick Thomas, Principal Scientist, GE Healthcare
Dr. Daniella Steel, Senior Principal Scientist, Cellartis
Dr. Julian Burke, Chief Executive Officer, Genetix
Dr. Dusko Ilic, Senior Lecturer in Stem Cell Science, King’s College London
Dr. Stephan Heyse, Head of Lead Discovery Informatics, Genedata
Post-conference workshop, 22nd September, 2010
Label-Free Cellular Assays: The Relevant Future of Drug Discovery
A review of label-free cell based assays - what they are, how they work and where they fit
Led by: Mr. Ryan McGuinness, Principal, Ryan McGuinness Consultants
Panelists: Dr. Matthew Peters, Principal Scientist, Lead Generation, AstraZeneca, Dr. Alastair Brown, Associate Principal Scientist, AstraZeneca,
Dr. Rochdi Bouhelal, Senior Investigator, Novartis and Dr. Magalie Rocheville, Investigator, Molecular Discovery Research, GlaxoSmithKline
Associate Sponsors
Junior Sponsors
Organised by
Driving the Industry Forward | www.futurepharmaus.com
Media Partners
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/assays
2. Conference Introduction
Cell-Based Assays
20th – 22nd September 2010
Dear Colleague, Poster Presentation
espite spiralling R&D costs, 90% of lead candidates identified by
D At a busy conference it is hard to make sure everyone who shares
current in vitro systems fail to become drugs. Setbacks including your interests knows what you are doing. Maximise your time at
poor efficacy and unanticipated side effects remain significant Visiongain’s Cell-based Assays meeting by sharing your results in a
poster presentation. With a plethora of key decision makers, take
challenges, frequently undetected in animal and pre-clinical testing.
advantage of this senior networking opportunity.
However, advances in microarray, label-free and stem cell platforms
are facilitating faster screening using human cells and dramatically Please send your 200 word abstract, in English, to:
improving next generation models. This 3-day event, comprising info@visiongainglobal.com for approval. The deadline for
pre-conference workshop and two-day meeting, provides practical submissions is Monday, October 18th, 2010. Please include contact
details for the corresponding author(s).
insights into the latest developments in this exciting field. With an
international faculty of leading experts, accelerate your product Academic institutions will not be charged a fee if booked as full-price
launches with insights from key decision makers. We bring you delegates. Posters submitted by pharmaceutical and biotechnology
distilled insights from outstanding speakers, in key areas including: firms will be charged a fee of £199.
Posters submitted by service providers / vendors are welcome and
• Whole-cell screening for GPCR ligands will be subject to evaluation. Upon approval a fee of £500 will apply.
Two delegates from your organisation must be booked at full price
to present a poster.
• Direct small-molecule kinase activation
Please note that all posters will be displayed at the discretion of
Visiongain Ltd and are subject to approval. Due to limited space,
• Advances and challenges in label-free technologies
please register your interest early.
• Induced pluripotent and hESCs for drug discovery
• Embryonic stem cell-derived hepatocytes and adult liver cells for Target Audience
CYP450 toxicity evaluation Presidents, Chief Executive Officers, VPs, Global Heads, Chief
Scientific Officers, Directors, Principal Scientists, Franchise Heads
and Investigators in:
• Accelerated high-content screening with human cardiac cells
• Bioanalytical Development
• High-Throughput/High-Content Screening Operations
• Neural progenitor cells for HT/uHT testing • Compound Profiling
• Drug Discovery/Validation
• Three-dimensional primary cell cultures for drug development • Drug Delivery
• Lead Generation
• In Vitro Sciences
• Cell migration and uptake assays
• ADMET
• Stability Testing
• Primary and three-dimensional culture methods for pharmacological
• Preformulation & Pre-Clinical Development
profiling • Biomarkers
• Toxicology
I look forward to meeting you at the conference • Stem Cell Technologies & Platforms
• Pharmacovigilance and Safety Testing
Best regards • Chemistry and Bioapplications
• GPCR/Kinases/Molecular Pharmacology
• External/Contract Research
• Pharmacokinetics/Pharmacodynamics
• Global Research and Development
John Shah
• Business Development
Conference Producer
• Investment and Venture Capital
3. Post-Conference Interactive Workshop
Cell-Based Assays
Wednesday, 22nd September 2010
Label-Free Cellular Assays: The Relevant Future of Drug Discovery
Led by: Mr. Ryan McGuinness Dr. Matthew Peters Timings: 9:30 - 10:00 Coffee & Registration
0
Principal Principal Scientist, Lead Generation 10:00 - 15:00 Workshop
Ryan McGuinness Consultants AstraZeneca
T
iming includes lunch and refreshment breaks
Dr. Magalie Rocheville Dr. Alastair Brown
Investigator, Molecular Discovery Research Associate Principal Scientist
GlaxoSmithKline AstraZeneca
Dr. Rochdi Bouhelal
Senior Investigator
Novartis
The purpose of the workshop is to allow you to engage in About your workshop leader:
knowledge sharing with your peers in a smaller, less formal Mr. Ryan McGuinness
environment than the main conference. As such, the audience
size will typically be no more than 20 participants in order to Ryan McGuinness was trained in genetics and
enable maximum interaction between the workshop leader cell biology at the University of California at
and the delegates. The format is also more interactive, with
Davis. Since 1988 he has worked in several
less emphasis on ‘lecture-style’ presentations and more
emphasis on group discussions, exercises and Q&A sessions. biotechnology companies and spent time
as a private research consultant. His research
Label-Free Cellular Assays:
background encompasses broad areas of molecular cell biology including
The Relevant Future of Drug Discovery
gene therapy, cellular therapeutics, receptor-mediated signal transduction
Today a majority of compound screening campaigns
performed by the Biopharmaceutical industry rely on and functional pharmacology. Ryan has also held customer-facing positions
cell-based assays for one particular reason: cell-based related to the introduction of novel technologies to the Biopharmaceutical
assays enable functional measures of target activation in a industry. He has most recently contributed his expertise to the development
more relevant and informative setting when compared to
biochemical assays. Label-free cellular assays are driving and commercialization of the CellKey System family of label-free products
this paradigm forward with their exquisite sensitivity, at MDS Analytical Technologies. Working at the forefront of label-free
robustness, ease of use and flexibility. These assays are now cell based assays Ryan has developed numerous applications, published
performed routinely throughout early drug discovery from
target identification and validation to primary screening, multiple scientific communications and lead collaborations world wide with
lead identification and lead optimization and into safety well-known drug discovery teams from companies like Merck, Amgen, J & J,
and toxicology. Through their sensitivity to endogenous Novartis and AstraZeneca.
levels of receptor targets in cell types closely aligned to the
disease processes under study, these technologies provide
highly accurate models of complex biological states in
formats compatible with industrialized drug screening.
Lessons Learned
During this workshop we will review the leading,
commercially available label-free cellular assay • n-depth understanding of the leading label-free cellular assay
I
platforms and discuss their applications, advantages technologies currently on the market.
and disadvantages. We will have a full discussion of the
underlying technology of each platform and compare their
• Discussion of label-free’s placement in the drug discovery process.
abilities to advance various stages of the drug discovery
process. We will also explore where label-free technologies
fit in the process and how they can be utilized to promote • dvantages and disadvantages of adopting label-free cell based
A
better decision making about which lead candidates to assay technologies.
advance. The future of these exciting new technologies is
in their ability to create opportunities for researchers to put • Case studies illustrating the utility of label-free assays.
a higher degree of cell biology into their drug discovery in
ways that until now were unattainable.
4. Day 1
Cell-Based Assays
Monday, 20th September 2010
09:00 Registration and refreshments 14:20 High-throughput 3D cell cultures for drug discovery
and human toxicology
09:30 Opening address from the Chairs • Cell-based microarray platforms
Dr. Rochdi Bouhelal
• Adoption of multiple cell-based assays into high-throughput format
Senior Investigator • Metabolism-based toxicity screening for pharmaceuticals and cosmetics
Novartis Dr. Jonathan Dordick
Director, Center for Biotechnology & Interdisciplinary Studies Rensselaer
09:40 Novel trends in high-throughput screening Polytechnic Institute
• The integrated approach to quantity, quality and cost efficiency
Co-Founder, Solidus Biosciences
• Single cell analysis vs. bulk cell assays
• Miniaturization towards future screening platforms
15:00 Fabricating, growing, assaying and storing 3D cell
Sara Lindström cultures: applications in drug discovery and beyond
Research & Development Manager • Drug discovery applications of 3D cell culture systems
PicoVitro • Label free cell and tissue mechanics assay system
• Cross talk between ontological drug targets and cardiac toxicity
10:20 Emerging GPCR assay technologies for drug discovery • Genomic effects on disease phenotypes
• Functional assays for GPCR drug discovery and uHTS • Development of cardiac tissue patches
• GPCR functional assays and assays to identify biased ligands
• abel-free and other assay technologies for GPCRs spanning from
L Dr. Tetsuro Wakatsuki
recombinant to physiologically relevant cell systems Chief Scientific Officer
InvivoSciences
Dr. Priya Kunapuli
Director, In Vitro Sciences 15:40 Afternoon refreshments
External Discovery and Pre-Clinical Sciences
Merck Research Laboratories 16:00 Cell-based assays and high-content imaging for early
identification of liver toxicity liability. What can be
11:00 Morning refreshments
predicted early in discovery and why bother?
11:20 Whole-cell label-free screening for GPCR ligands • When does it make sense to identify toxicity liabilities early?
• irect comparison of impedance-based (CellKey) and optical-based
D • Which liabilities can be predicted in early discovery?
instruments (BIND and Epic) for Gi, Gq, and Gs-coupled receptors • Which in vitro assays have enough validation behind them?
• etecting and distinguishing activation of multiple G-proteins and thus
D Katya Tsaioun
functional selectivity President, Scientific Director and Co-Founder
• An expanding niche for label-free approaches in GPCR screening Apredica
Dr. Matthew Peters
Principal Scientist, Lead Generation 16:20 SimuGen: effective modelling of in vitro genomic
AstraZeneca and high content screening data for drug discovery
• urrent toxicogenomic failures due to expense, complexity and lack of
C
12:00 Use of xCELLigence technology for uncovering novel scalability for early stage screening
functional outputs regulated by the cAMP signalling • Human dose-response models developed by SimuGen
• imuGen’s flagship liver toxicity product and the HT-Stream software
S
pathway developed by SimuGen for in vitro predictive toxicology
• CELLigence as a tool to monitor the onset of hypertrophy in neonatal
x
cardiac myocyte cultures Dr. Quin Wills
• xCELLigence can monitor changes in barrier function in endothelial cells CSO and Co-Founder
• nhibition of cancer cell growth by modulation of the cAMP signalling
I SimuGen
pathway
Dr. George S. Baillie 16:40 A network view of disease and compound screening
Lecturer, Neuroscience and Molecular Pharmacology T
opics discussed will include: utilising diverse screening methodologies to
University of Glasgow maximise lead optimisation, and moving towards physiologically relevant disease
PANEL DISCUSSION
models for more accurate lead identification. The impact of chemical biology
12:20 Accelerated high-content screening to identify integrated networks in disease, and prospects for HT screens on
• Cell-cycle specific assays personalized drug discovery will also be discussed. Please email any questions
you have for the panel to: john.shah@visiongainglobal.com.
• Apoptosis and cell death
Chair: Dr. Maria Flocco, Senior Director, Lead Discovery and Structural
Dr. Julian Burke
Biology & Biophysics, Pfizer
Chief Scientific Officer
Genetix Dr. Priya Kunapuli, Director, In Vitro Sciences, External Discovery and
Pre-Clinical Sciences , Merck Research Laboratories
13:00 Networking lunch Dr. Jonathan Dordick, Director, Center for Biotechnology & Interdisciplinary
14:00 Image analysis for quantitative cell-based assays Studies Rensselaer Polytechnic Institute, Co-Founder, Solidus Biosciences
• myWim - Platform independent solution for high reliability Dr. Stephan Heyse, Head of Lead Discovery Informatics, Genedata
• Assay-specific algorithm design for precise results
• Standardized metric system for multi-site research comparability
• WimScratch - A solution for migratory response evaluation 17:20 Closing remarks from the chair
Mr. Kilian C.M. Schramm
Chief Executive Officer & Co-Founder 17:30 Networking drinks
Wimasis
Take your discussions further and build new
relationships in a relaxed and informal setting.
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2010
5. Day 2
Cell-Based Assays
Tuesday, 21st September 2010
09:00 Registration and refreshments 14:20 Use of human pluripotent stem cell derived
cardiomyocytes for drug discovery and development
09:30 Opening address from the chair • Derivation and characteristics of cardiomyocytes from hESC
• Utility of hESC-derived cardiomyocytes for cardiotoxicity testing
Dr. Stefan O. Mueller
Global Head, Early, Genetic and Molecular Toxicology • Validation and bench-marking to existing models
Merck Serono Dr. Daniella Steel
Senior Principal Scientist
09:40 Screening tools for toxicity and drug discovery Cellartis
• Overview on screening tools for discovery toxicology
• Use of omics to explain and predict toxicities 15:00 Afternoon refreshments
• Hepatocytes for ADMET
Dr. Stefan O. Mueller
Global Head, Early, Genetic and Molecular Toxicology
Merck Serono 15:20 Stem cells in drug development- where are we and
what are prospects for the future?
10:20 Human hepatocytes as an effective alternative T
opics discussed will include: advantages and disadvantages over human
experimental system for the evaluation of human primary cells, efficacy in pre-clinical testing, and current safety challenges.
Please email any questions you have for the panel to: john.shah@
drug properties PANEL DISCUSSION
visiongainglobal.com.
• Metabolic stability
Dr. Dusko Ilic
• Drug-drug interactions and toxicity evaluation
Senior Lecturer in Stem Cell Science
• Transporter studies King’s College London
Dr. Albert Li Dr. Nick Thomas
President and Chief Executive Officer Principal Scientist
Advanced Pharmaceutical Sciences GE Healthcare
Dr. Daniella Steel
11:00 Morning refreshments
Senior Principal Scientist
Cellartis
11:20 Human embryonic stem cells in drug testing and
discovery Senior representative
CELLular Dynamics international
• hESCs as a model for embryotoxicity screening
• Disease-specific hESCs in biomarker and drug discovery
• hat is preventing hESC utilisation at the rapid pace that befits their
W
enormous potential?
16:00 A novel imaging-based high-throughput screening
Dr. Dusko Ilic
Senior Lecturer in Stem Cell Science
approach to anti-angiogenic drug discovery
King’s College London • Limitations of current HTS compound screening
• n organotypic EC-vSMC co-culture assay system compatible with high-
A
throughput/high-content image screening
12:00 Introducing the BIND® scanner– high resolution,
• Quantitative evaluation of anti-angiogenic inhibitors
label-free applications for primary cultured cells
• Toxicity assays with ES-derived cardiomyocytes and hepatocytes Dr. David Micklem
• Stem cell differentiation assays Chief Scientific Officer
BerGenBio
• Transwell-free chemotaxis assays
Dr. Steven Shamah 16:40 Primary brain cells for drug screening: the brain chip
Director of Cell Biology
platform
SRU Biosystems
• Use of primary neurons for high content screening
• Dissecting cell-cell signaling in neuroinflammation
12:40 Networking lunch
Dr. Fabio Bianco
13:40 Cell models and assays for investigative toxicology Chief Executive Officer
Neuro-Zone
• hESC derived cell models for hepatotoxicity and cardiotoxicity
• High content analysis for cellular toxicity
17:20 Chair’s closing remarks
• Electrophysiology for cardiotoxicity
Dr. Nick Thomas 17:30 End of conference
Principal Scientist
GE Healthcare
6. Partners
Cell-Based Assays
20th – 22nd September 2010
Associate Sponsors: Media Partners:
At Roche Applied Science we are committed to providing innovative, PharmiWeb.com is the leading industry-sponsored portal for
high-quality instruments and reagents combined with excellent the pharmaceutical sector. Supported by most of the leading
customer service – offering powerful tools to address the evolving pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news,
needs of life science researchers worldwide. We offer real-time label-free cell analysis features, events listings and international jobs to industry professionals across Europe
with the xCELLigence system, automated imaged-based cell monitoring with the and the US.
Cellavista system, and a range of cell-counting technologies with our Cedex XS and For further information please email: corporate@pharmiweb.com
CASY systems. Coupled with a wide range of cell biology products, and our established
portfolio of genomics and proteomics systems and reagents, Roche Applied Science is
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY
with you every step of the way.
WORLD. It is based and located in Warsaw, Poland. Biotechnology
For further information please visit: www.roche.com World was founded in 2007 to provide the world’s biotech and pharma information
and market to make it universally accessible and useful for scientific and business
processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY
EUROPE platform that will allow a quick spread of information in different channels.
BIOTECHNOLOGY EUROPE offers companies completed internet public relations,
publication and marketing solutions. One of the mains goals of BIOTECHNOLOGY
For further information please visit: www.invivosciences.com EUROPE is to integrate the Biotech and Pharma Sector in Europe to global
biotechnology, pharmaceutical and life science activities.
Bionas® specializes in instruments and services for label-free, For further information please visit: www.biotechnology-europe.com
cell-based assays. The B2500 analyzing system is a 6 channel
system for the simultaneous monitoring of oxygen consumption, Future Pharmaceuticals has forged powerful relationships
Driving the Industry Forward | www.futurepharmaus.com
acidification and cellular impedance/adhesion. The instrument generates real-time
with key industry leaders to provide a platform for successful
data about the metabolic activity of cells, including regeneration effects. Adherent, brand recognition, and for senior decision-makers to have the means to procure and
primary or suspension cells can be analyzed for applications in toxicology, oncology, plan implementation strategies based on the topics covered. Positioned to be an
drug discovery. The B9600 adcon reader is a versatile instrument for label-free authoritative resource within top pharma companies as well as small, specialty, and
monitoring of cellular impedance in 96 well format. It provides real-time information biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into
about cell adhesion, proliferation, morphology etc. for high-throughput screening and a highly targeted and responsive audience, bridging the gap between the industries’
laboratory research. GLP laboratory service is also available. top issues and the solutions top-tier vendors can provide.
For further information please visit: www.bionas.de For further information please visit: www.futurepharmaus.com
Cellular Dynamics International is the world’s largest producer
InPharm is the online platform for exclusive pharmaceutical
of fully functional human cells derived from induced pluripotent
news, comment, contracts, services, jobs and events and is home
stem (iPS) cells. Our iCell™ product lines provide industrialized
to InPharmjobs.com, Pharmafile and Pharmafocus.
quantities of pure, homogenous, terminally differentiated human cells enabling basic
research, efficient drug discovery programs, and reliably predictive toxicity and efficacy
For further information please visit: www.In-Pharm.com
screening through in vitro clinical trials.
For further information please visit: www.cellulardynamics.com Pharma Connections Worldwide® is the leading professional
business networking website focused in the Pharmaceutical,
The Wimasis GmbH is a provider of quantitative image analysis Biotechnology and Life Sciences research industry. Our goal is to provide a conduit
solutions that run online. The platform doesn’t require any software for delivery of premiere content coupled with the right clientele in order to facilitate
installation or specialized hardware equipment. Simply by accessing business development opportunities among industry professionals responsible for
https://mywim.wimasis.com/ through the browser, users can conduct the quantitative making key decisions in a global marketplace.
image analysis from anywhere in the world. Just upload your images, start the analysis For further information please visit: www.pharmaconnections.com
process and receive the results via email and as a downloadable detailed report.
Migration Assays, Chemotaxis Assays (beta phase), Angiogenesis Assays (beta phase),
Autophagy Assays and Custom Solutions are available to fit your needs.
For further information please visit: www.wimasis.com
Sponsorship and exhibition opportunities:
Junior Partners:
SimuGen is a pharmacogenomics company focused on early stage This event offers a unique opportunity to meet and do business with some
drug discovery. The company combines groundbreaking human of the key players in the pharmaceutical and biotech industries. If you have a
cell culture and genomic modelling to produce high throughput
screens for use alongside other early ADME testing. SimuGen’s fl agship product,
service or product to promote, you can do so at this event by:
HT-Stream, is software that allows you to model in vitro genomic and high-content
screening data to predict human toxicities and the doses at which these toxicities • Hosting a networking drinks reception
emerge. The software is easy to understand, decision-centric, and has features
allowing you to input prior ADME knowledge and relate results back to structure- • Taking an exhibition space at the conference
activity modelling. For more information on HT-Stream and how to use SimuGen’s
hepaRG liver tox models for your in vitro screening please visit www.simugen-global. • Advertising in the delegate documentation pack
com and contact quin.wills@simugen-global.com.
For further information please visit: www.simugen-global.com • Providing branded bags, pens, gifts, etc.
If you would like more information on the range of sponsorship or exhibition
possibilities for visiongain's Cell-Based Assay Conference, please contact us:
Ronald Reyes Magali, +44 (0)20 7549 9934
For further information please visit: www.Apredica.com ronald.magali@visiongainglobal.com
Christopher Clegg, +44 (0)20 7549 9964
christopher.clegg@visiongainglobal.com
7. Registration Form
Cell-Based Assays
20th – 22nd September 2010
Angel
For multiple bookings Pentonville Road
Photocopy this form Conf. code VG Cell-Based Assays
Ci
t
ty
Ro
ad
Standard Prices 20th - 22nd September 2010
Conference and workshop Fee: £1699 VAT: £297.33 Total: £1996.33 Location: SG Conference Centre
B Old Street
Conference only Fee: £1299 VAT: £227.33 Total: £1526.33 Address: Old Street
Workshop only Fee: £599 VAT: £104.83 Total: £703.83 226-236 City Road
London
City Road
Promotional Literature Distribution EC1V 2TT
UK
Distribution of your company’s promotional literature to all conference attendees
Fee: £999 VAT: £174.83 Total: £1173.83
Details
How to book
Forename: Surname: Email: conferences@visiongainglobal.com
Web: http://www.visiongain.com/assays
Job Title: Company: UK Office:
Tel: +44(0) 20 7336 6100
Main Switchboard Number: Fax: +44(0) 20 7549 9932
Visiongain Ltd
Address: BSG House
226-236 City Road
London
EC1V 2QY
UK
Country: Postcode:
General information
Venue: Directions: BSG Conference Centre 226 – 236 City Road, London, EC1V 2TT. United
Phone: Fax: Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Travelodge London City
Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503,
Email: http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Signature: Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may
be requested if payment has not been received in full before the event. Visiongain Ltd reserves the
I confirm that I have read and agree to the terms and conditions of booking
right to charge interest on unpaid invoices.
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
Methods of payment after one month before the start of the event. Should you decide to cancel after this date, the full invoice
must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
Payment must be made in sterling
between conferences. However, if you cannot attend the conference, you may make a substitution/name
By Mail: Complete and return your signed registration form together with your cheque payable change at any time, as long as we are informed in writing by email, fax or post. Name changes and
substitutions must be from the same company or organisation and are not transferable between
to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK countries. Please note that discounted delegates places at a visiongain event are non refundable.
By Fax: Complete and fax your signed registration form with your credit card details Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
excluding substitutions/name changes, requested by the customer. This will be charged to the
to +44 (0) 20 7549 9932 customer by credit card prior to the changes being made.
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
By Bank Transfer: expenses, which may be incurred by the customer as a consequence of the event being postponed or
Visiongain Ltd A/C: visiongain Ltd cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
cost of the registration, travel and expenses.
Barclays Bank Sort Code: 20-71-64
Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
Piccadilly Branch Account No: 6038 7118 Protection Act 1988. Your personal information contained in this form may be used to update you on
48 Regent Street Swift Code: BARC GB22 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
London, W1B 5RA IBAN: GB80 BARC 20716460387118 wish for your details to be amended, suppressed or not passed on to any external third party, please
send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
Please debit my credit card:
EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Access MasterCard Visa American Express Please allow approximately 30 days for your removal or update request to be applied to our database.
Following your removal or update request, you may receive additional pieces of communication from
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
Card number:
This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT
Expiry Date: incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com.
Eurocash specialise in recovering cross-border VAT.
Security number (last 3 digits on back of credit card): How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Signature:
Unable to attend
Cardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
with your payment. You will receive your copy of the event CD Rom two weeks after the event.
Yes, please send me a copy of the CD for Price:£550 VAT:£96.25 Total:£646.25
News updates
Office use only
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/assays